Liver Cancer
Can-Fite Successfully Completes Preclinical Trials With Its Second Drug Candidate CF102
Published in Hepatitis Weekly, September 3rd, 2007
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, announced the successful completion of preclinical trials with CF102, the second molecule in the Company's development pipeline, which is the basis for a drug indicated for the treatment of liver cancer and hepatitis. Success of the preclinical trials will enable Can-Fite to submit to the US Food and Drug Administration (FDA) an application for phase I human clinical trials. The Company estimates that the clinical phase of the trials will begin in the up-coming months.
Can-Fite VP Drug Development Dr. William Kerns: "CF102 has been evaluated in an IND enabling pharmacokinetic,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-09-03)
More Articles from Hepatitis Weekly
- HIV/AIDS
BIT225 Phase I Clinical Trial Successfully Completed - Coagulation Therapy
University Medical Center reports research in coagulation therapy - DNA Vaccines
Studies from S. Mahor and colleagues reveal new findings on DNA vaccines - Hepatitic B Vaccines
Studies in the area of hepatitic b vaccines reported from Chung-Shan Medical University, Department of Family Medicine - Hepatitis A Virus Genetics
Reports summarize hepatitis A virus genetics research from J. Cristina and co-authors - Hepatitis B Virus
Findings from H. Bai and co-authors provide new insights into hepatitis B virus - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
